NATCO Pharma Management
Management criteria checks 1/4
NATCO Pharma's CEO is Rajeev Nannapaneni, appointed in Jun 2012, has a tenure of 12.42 years. directly owns 0.63% of the company’s shares, worth ₹1.55B. The average tenure of the management team and the board of directors is 7.8 years and 1.4 years respectively.
Key information
Rajeev Nannapaneni
Chief executive officer
₹98.7m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 12.4yrs |
| CEO ownership | 0.6% |
| Management average tenure | 7.8yrs |
| Board average tenure | 1.4yrs |
Recent management updates
Recent updates
NATCO Pharma (NSE:NATCOPHARM) Has Announced A Dividend Of ₹1.50
Nov 18
Earnings Beat: NATCO Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Nov 15We Ran A Stock Scan For Earnings Growth And NATCO Pharma (NSE:NATCOPHARM) Passed With Ease
Oct 13NATCO Pharma Limited's (NSE:NATCOPHARM) Shares Bounce 26% But Its Business Still Trails The Market
Aug 13If EPS Growth Is Important To You, NATCO Pharma (NSE:NATCOPHARM) Presents An Opportunity
Jul 15NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly
Jun 30NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings Are Not Doing Enough For Some Investors
Jun 14NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models
May 30Calculating The Fair Value Of NATCO Pharma Limited (NSE:NATCOPHARM)
May 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Apr 03NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25
Feb 21NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next
Feb 18NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement
Feb 17Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jan 25An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued
Jan 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Dec 13An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued
Sep 30Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today
Sep 12NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year
Aug 12Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jul 16NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate
Apr 20Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?
Dec 20NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's
Aug 12Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?
Jun 23Broker Revenue Forecasts For NATCO Pharma Limited (NSE:NATCOPHARM) Are Surging Higher
Jun 02CEO
Rajeev Nannapaneni (47 yo)
12.4yrs
Tenure
₹98,670,000
Compensation
Sri Rajeev Nannapaneni serves as Chief Executive Officer at NATCO Pharma Limited since April 1, 2022 and also served as Vice Chairman since June 1, 2012 until April 1, 2022 and serves as its Vice Chairman...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Chairman | 43.2yrs | ₹100.77m | 25.1% ₹ 61.8b | |
| CEO & Vice Chairman | 12.4yrs | ₹98.67m | 0.63% ₹ 1.6b | |
| Chief Financial Officer | 8.8yrs | ₹13.36m | no data | |
| President of Technical Affairs & Whole Time Director | no data | ₹33.69m | 0.030% ₹ 74.5m | |
| Company Secretary & Compliance Officer | 2.6yrs | ₹2.61m | no data | |
| Executive VP of Corporate Engineering Services & Whole Time Director | no data | ₹20.16m | 0.023% ₹ 56.6m | |
| Executive VP of Technical Operations & Director | 7.8yrs | ₹32.12m | 0.013% ₹ 32.0m | |
| VP & Head of Operations | no data | no data | no data | |
| Executive Vice President of Corporate Affairs | no data | no data | no data | |
| Vice President of Marketing & Sales - Domestic | less than a year | no data | no data | |
| Senior Vice President of HR & Organisational Development | no data | no data | 0.0062% ₹ 15.3m | |
| Executive Vice President of R&D | 30.6yrs | no data | 0.025% ₹ 60.6m |
7.8yrs
Average Tenure
65yo
Average Age
Experienced Management: NATCOPHARM's management team is seasoned and experienced (7.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Chairman | 43.2yrs | ₹100.77m | 25.1% ₹ 61.8b | |
| CEO & Vice Chairman | 19yrs | ₹98.67m | 0.63% ₹ 1.6b | |
| President of Technical Affairs & Whole Time Director | 9.8yrs | ₹33.69m | 0.030% ₹ 74.5m | |
| Executive VP of Corporate Engineering Services & Whole Time Director | 10yrs | ₹20.16m | 0.023% ₹ 56.6m | |
| Executive VP of Technical Operations & Director | 2.3yrs | ₹32.12m | 0.013% ₹ 32.0m | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | no data |
1.4yrs
Average Tenure
62.5yo
Average Age
Experienced Board: NATCOPHARM's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.